The Meaning of Myriad
Friday, September 12, 2014
9:00 a.m.–5:00 p.m.
University of California, Irvine
In 2013, the United States Supreme Court rendered its decision on gene patenting in Association of Molecular Pathology v. Myriad Genetics, ending 30 years of United States Patent Office patent practice and seemingly placing the United States out of step with the patent policy of many of its trading partners. A year later, the reasoning of the Myriad decision itself remains anything but clear, as does its potential effect on the patent eligibility of other technologies and on the patent policy of other jurisdictions. This conference will explore the evolving meaning of the Myriad decision for science, for industry, and for the patent system.
CLE credit available.
Hon. Andrew Guilford, USDC Cent. Dist. Cal
- Dan Burk, University of California, Irvine
- Mark Janis, University of Indiana—Bloomington
- Anna Laakman, Lewis & Clark University
- Jessica Lai, University of Lucerne
- Peter Lee, University of California, Davis
- Mark Lemley, Stanford University
- Lisa Larrimore Ouellette, Stanford University
- Amelia Rinehart, University of Utah
- Brad Sherman, Griffith University